These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 9644298)
1. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Martino R; Subira M; Altés A; López R; Sureda A; Domingo-Albós A; Pericas R; Brunet S Acta Haematol; 1998; 99(4):206-11. PubMed ID: 9644298 [TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Kern WV; Klose K; Jellen-Ritter AS; Oethinger M; Bohnert J; Kern P; Reuter S; von Baum H; Marre R Eur J Clin Microbiol Infect Dis; 2005 Feb; 24(2):111-8. PubMed ID: 15714332 [TBL] [Abstract][Full Text] [Related]
3. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Bow EJ; Mandell LA; Louie TJ; Feld R; Palmer M; Zee B; Pater J Ann Intern Med; 1996 Aug; 125(3):183-90. PubMed ID: 8686975 [TBL] [Abstract][Full Text] [Related]
4. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505 [TBL] [Abstract][Full Text] [Related]
5. [Prophylaxis with fluoroquinolones in patients with neutropenia]. Brodsky AL; Minissale CJ; Melero MJ; Sánchez Avalos JC Medicina (B Aires); 1993; 53(5):401-7. PubMed ID: 8201928 [TBL] [Abstract][Full Text] [Related]
6. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Gomez L; Garau J; Estrada C; Marquez M; Dalmau D; Xercavins M; Martí JM; Estany C Cancer; 2003 Jan; 97(2):419-24. PubMed ID: 12518366 [TBL] [Abstract][Full Text] [Related]
7. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia. Verlinden A; Jansens H; Goossens H; van de Velde AL; Schroyens WA; Berneman ZN; Gadisseur AP Eur J Haematol; 2014 Oct; 93(4):302-8. PubMed ID: 24750350 [TBL] [Abstract][Full Text] [Related]
8. Tosulfloxacin versus norfloxacin for prevention of infections in chemotherapy-induced neutropenic patients. Mori S; Ohashi K; Akiyama H; Shoji H; Sato H; Tanikawa S; Sakamaki H; Onozawa Y Kansenshogaku Zasshi; 1994 Jul; 68(7):872-8. PubMed ID: 8089554 [TBL] [Abstract][Full Text] [Related]
9. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Ann Intern Med; 1991 Jul; 115(1):7-12. PubMed ID: 2048868 [TBL] [Abstract][Full Text] [Related]
10. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City]. Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285 [TBL] [Abstract][Full Text] [Related]
11. Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation. Menichetti F; Felicini R; Bucaneve G; Aversa F; Greco M; Pasquarella C; Moretti MV; Del Favero A; Martelli MF Bone Marrow Transplant; 1989 Sep; 4(5):489-92. PubMed ID: 2790326 [TBL] [Abstract][Full Text] [Related]
12. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children--perspective randomized study. Cruciani M; Concia E; Navarra A; Perversi L; Bonetti F; Aricò M; Nespoli L Infection; 1989; 17(2):65-9. PubMed ID: 2654019 [TBL] [Abstract][Full Text] [Related]
13. Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients. D'Antonio D; Iacone A; Fioritoni G; Betti S; Dell'Isola M; Quaglietta AM; Accorsi P; Pantalone V; Recchia A; Piergallini A Drugs Exp Clin Res; 1992; 18(4):141-6. PubMed ID: 1451644 [TBL] [Abstract][Full Text] [Related]
14. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Chong Y; Yakushiji H; Ito Y; Kamimura T Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723 [TBL] [Abstract][Full Text] [Related]
15. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Ortiz J; Vila MC; Soriano G; Miñana J; Gana J; Mirelis B; Novella MT; Coll S; Sábat M; Andreu M; Prats G; Solá R; Guarner C Hepatology; 1999 Apr; 29(4):1064-9. PubMed ID: 10094947 [TBL] [Abstract][Full Text] [Related]
16. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Carratalá J; Fernández-Sevilla A; Tubau F; Callis M; Gudiol F Clin Infect Dis; 1995 Mar; 20(3):557-60; discussion 561-3. PubMed ID: 7756475 [TBL] [Abstract][Full Text] [Related]
17. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Fernández J; Ruiz del Arbol L; Gómez C; Durandez R; Serradilla R; Guarner C; Planas R; Arroyo V; Navasa M Gastroenterology; 2006 Oct; 131(4):1049-56; quiz 1285. PubMed ID: 17030175 [TBL] [Abstract][Full Text] [Related]
18. [Clinical study on fluoroquinolone prophylaxis in neutropenia patients with acute leukemia]. Qin TJ; Mi YC; Feng SZ; Li DP; Wei JL; Yang DL; Han MZ; Wang JX; Bian SG Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1389-93. PubMed ID: 17785058 [TBL] [Abstract][Full Text] [Related]
19. Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case controlled study. Krcméry V; Spanik S; Krupova I; Trupl J; Kunova A; Smid M; Pichnova E J Chemother; 1998 Aug; 10(4):320-5. PubMed ID: 9720472 [TBL] [Abstract][Full Text] [Related]
20. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Rangaraj G; Granwehr BP; Jiang Y; Hachem R; Raad I Cancer; 2010 Feb; 116(4):967-73. PubMed ID: 20052728 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]